<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02953587</url>
  </required_header>
  <id_info>
    <org_study_id>111237-Protocol II</org_study_id>
    <secondary_id>R01DK091748</secondary_id>
    <nct_id>NCT02953587</nct_id>
  </id_info>
  <brief_title>Effect of Ghrelin on Glucose Metabolism After Bariatric Surgery</brief_title>
  <official_title>Effect of Ghrelin on Glucose Metabolism After Bariatric Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vanderbilt University Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Vanderbilt University Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine if the altered nutrient exposure to the GI tract
      after bariatric surgery reveals a negative incretin effect of ghrelin.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>September 2016</start_date>
  <completion_date type="Anticipated">September 2019</completion_date>
  <primary_completion_date type="Anticipated">September 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in plasma glucose levels with ghrelin versus saline.</measure>
    <time_frame>1 month (before and after surgery)</time_frame>
    <description>The objective for this protocol is to determine if ghrelin infusion worsens glucose tolerance during jejunal administration of glucose and if the response is difference after bariatric surgery (RYGB or VSG).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Plasma insulin levels</measure>
    <time_frame>1 month (before and after surgery)</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Plasma Levels of GLP-1</measure>
    <time_frame>1 month (before and after surgery)</time_frame>
    <description>Metabolic panel to include plasma levels of GLP-1</description>
  </other_outcome>
  <other_outcome>
    <measure>Plasma Levels of GIP</measure>
    <time_frame>1 month (before and after surgery)</time_frame>
    <description>Metabolic panel to include plasma levels of GIP</description>
  </other_outcome>
  <other_outcome>
    <measure>Plasma Levels of leptin</measure>
    <time_frame>1 month (before and after surgery)</time_frame>
    <description>Metabolic panel to include plasma levels of leptin</description>
  </other_outcome>
  <other_outcome>
    <measure>Plasma Levels of pancreatic polypeptide</measure>
    <time_frame>1 month (before and after surgery)</time_frame>
    <description>Metabolic panel to include plasma levels of pancreatic polypeptide</description>
  </other_outcome>
  <other_outcome>
    <measure>Plasma Levels of Peptide YY (PYY)</measure>
    <time_frame>1 month (before and after surgery)</time_frame>
    <description>Metabolic panel to include plasma levels of PYY</description>
  </other_outcome>
  <other_outcome>
    <measure>Plasma Levels of C-Peptide</measure>
    <time_frame>1 month (before and after surgery)</time_frame>
    <description>Metabolic panel to include plasma levels of C-Peptide</description>
  </other_outcome>
  <other_outcome>
    <measure>Plasma Levels of glucagon</measure>
    <time_frame>1 month (before and after surgery)</time_frame>
    <description>Metabolic panel to include plasma levels of glucagon</description>
  </other_outcome>
  <other_outcome>
    <measure>Plasma Levels of Cholecystokinin (CCK)</measure>
    <time_frame>1 month (before and after surgery)</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Plasma Levels of Cholecystokinin Adrenocorticotropic Hormone (ACTH)</measure>
    <time_frame>1 month (before and after surgery)</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Plasma Levels of Human Growth Hormone (HGH)</measure>
    <time_frame>1 month (before and after surgery)</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Plasma Levels of Cortisol</measure>
    <time_frame>1 month (before and after surgery)</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Plasma Levels of insulin-like growth factor 1 (IGF-1)</measure>
    <time_frame>1 month (before and after surgery)</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Acyl and desacyl ghrelin</measure>
    <time_frame>1 month (before and after surgery)</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Plasma Levels of Bile Acids</measure>
    <time_frame>1 month (before and after surgery)</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Plasma Levels of Free Fatty Acids (FFAs)</measure>
    <time_frame>1 month (before and after surgery)</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Plasma Levels of Triglycerides (TG)</measure>
    <time_frame>1 month (before and after surgery)</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Performance on Visual Analog Scale for Hunger</measure>
    <time_frame>1 month (before and after surgery)</time_frame>
  </other_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">70</enrollment>
  <condition>Obesity</condition>
  <arm_group>
    <arm_group_label>Vertical Sleeve Gastrectomy (VSG) NJ/PO</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients that are undergoing routine VSG will be studied preoperatively, and at 1 month postoperatively. Each time point will have two study visits with a cross-over design. The first visit at each time point will be randomized to a human ghrelin or a saline infusion, with the alternate infusion at the second visit. At each study visit, an Oral Glucose Tolerance Test (OGTT) will be performed by administering glucose through a nasojejunal (NJ) feeding tube preoperatively and orally (PO) postoperatively.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Roux-en-Y Gastric Bypass (RYGB) NJ/PO</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients that are undergoing routine RYGB will be studied preoperatively, and at 1 month postoperatively. Each time point will have two study visits with a cross-over design. The first visit at each time point will be randomized to a human ghrelin or a saline infusion, with the alternate infusion at the second visit. At each study visit, an Oral Glucose Tolerance Test (OGTT) will be performed by administering glucose through a nasojejunal (NJ) feeding tube preoperatively and orally (PO) postoperatively.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vertical Sleeve Gastrectomy (VSG) PO/PO</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients that are undergoing routine VSG will be studied preoperatively, and at 1 month postoperatively. Each time point will have two study visits with a cross-over design. The first visit at each time point will be randomized to a human ghrelin or a saline infusion, with the alternate infusion at the second visit. At each study visit, an Oral Glucose Tolerance Test (OGTT) will be performed.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Roux-en-Y Gastric Bypass (RYGB) PO/PO</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients that are undergoing routine RYGB will be studied preoperatively, and at 1 month postoperatively. Each time point will have two study visits with a cross-over design. The first visit at each time point will be randomized to a human ghrelin or a saline infusion, with the alternate infusion at the second visit. At each study visit, an Oral Glucose Tolerance Test (OGTT) will be performed.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Oral Glucose Tolerance Test (OGTT)</intervention_name>
    <description>Subjects will have glucose administered enterally and blood will be drawn to measure its kinetics.</description>
    <arm_group_label>Vertical Sleeve Gastrectomy (VSG) NJ/PO</arm_group_label>
    <arm_group_label>Roux-en-Y Gastric Bypass (RYGB) NJ/PO</arm_group_label>
    <arm_group_label>Vertical Sleeve Gastrectomy (VSG) PO/PO</arm_group_label>
    <arm_group_label>Roux-en-Y Gastric Bypass (RYGB) PO/PO</arm_group_label>
    <other_name>OGTT</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Human Ghrelin</intervention_name>
    <description>Human ghrelin will be administered by IV at two of the four study visits in conjunction with the OGTT.</description>
    <arm_group_label>Vertical Sleeve Gastrectomy (VSG) NJ/PO</arm_group_label>
    <arm_group_label>Roux-en-Y Gastric Bypass (RYGB) NJ/PO</arm_group_label>
    <arm_group_label>Vertical Sleeve Gastrectomy (VSG) PO/PO</arm_group_label>
    <arm_group_label>Roux-en-Y Gastric Bypass (RYGB) PO/PO</arm_group_label>
    <other_name>Ghrelin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Saline</intervention_name>
    <description>Saline Infusion will be administered by IV at two of the four study visits in conjunction with the OGTT to serve as a placebo comparator for the human ghrelin infusions.</description>
    <arm_group_label>Vertical Sleeve Gastrectomy (VSG) NJ/PO</arm_group_label>
    <arm_group_label>Roux-en-Y Gastric Bypass (RYGB) NJ/PO</arm_group_label>
    <arm_group_label>Vertical Sleeve Gastrectomy (VSG) PO/PO</arm_group_label>
    <arm_group_label>Roux-en-Y Gastric Bypass (RYGB) PO/PO</arm_group_label>
    <other_name>NaCl, sodium chloride</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  BMI ≥ 35 kg/m2

          -  Age 21-65 years

          -  Weight ≤ 200 kg

        Exclusion Criteria:

          -  Type 2 or Type 1 diabetes

          -  Medications that alter insulin sensitivity or carbohydrate metabolism

          -  Positive pregnancy test

          -  Known history of intestinal diseases including, but not limited to, inflammatory bowel
             disease (e.g. Chronic Ulcerative Colitis, Crohn's disease, celiac sprue)

          -  Prior gastric or intestinal surgery or pancreas resection

          -  History of cardiovascular disease, including but not limited to: myocardial
             infarction, angioplasty, arrhythmia, uncontrolled hypertension

          -  History of chronic kidney disease or renal insufficiency; creatinine &gt; 1.8 mg/dl.

          -  History of chronic liver disease, including but not limited to: cirrhosis, hepatitis,
             portal hypertension; AST and/or ALT &gt; 2x the upper limit of normal.

          -  Abnormal ECG
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Vanderbilt University Medical Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 22, 2016</study_first_submitted>
  <study_first_submitted_qc>October 31, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 3, 2016</study_first_posted>
  <last_update_submitted>May 18, 2018</last_update_submitted>
  <last_update_submitted_qc>May 18, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 21, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Vanderbilt University Medical Center</investigator_affiliation>
    <investigator_full_name>Naji Abumrad</investigator_full_name>
    <investigator_title>John L. Sawyers Professor of Surgery</investigator_title>
  </responsible_party>
  <keyword>Obesity</keyword>
  <keyword>Bariatric Surgery</keyword>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

